{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:57:51Z","timestamp":1791824271252,"version":"4.3.4"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00210-026-05574-5","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T02:45:10Z","timestamp":1782096310000},"page":"18691-18720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ulcerative colitis: from molecular pathophysiology to management and the emerging role of natural and pharmacological drug candidates"],"prefix":"10.1007","volume":"399","author":[{"given":"Ehab E.","family":"Sharata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Bakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hager","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham H.","family":"Mohyeldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remon Roshdy","family":"Rofaeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramadan A. M.","family":"Hemeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al Shaimaa Mahmoud","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abdelnaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"8","key":"5574_CR1","volume":"9","author":"HM Abdallah","year":"2020","unstructured":"Abdallah HM, Ammar NM, Abdelhameed MF, Gendy A-N, Ragab TI, Abd-ElGawad AM, Farag MA, Alwahibi MS, Elshamy AI (2020) Protective mechanism of Acacia saligna butanol extract and its nano-formulations against ulcerative colitis in rats as revealed via biochemical and metabolomic assays. Biology (Basel) 9(8):195","journal-title":"Biology (Basel)"},{"key":"5574_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.887233","volume":"13","author":"AM Abdelhamid","year":"2022","unstructured":"Abdelhamid AM, Youssef ME, Cavalu S, Mostafa-Hedeab G, Youssef A, Elazab ST, Ibrahim S, Allam S, Elgharabawy RM, El-Ahwany E (2022) Carbocisteine as a modulator of Nrf2\/HO-1 and NF\u03baB interplay in rats: new inspiration for the revival of an old drug for treating ulcerative colitis. Front Pharmacol 13:887233","journal-title":"Front Pharmacol"},{"issue":"2\/24","key":"5574_CR3","volume":"2","author":"O Abdullayeva","year":"2025","unstructured":"Abdullayeva O, Abdullayev V (2025) On non-specific ulcerative colitis (ulcerative colitis, Uc). J Med 2(2\/24):30","journal-title":"J Med"},{"key":"5574_CR4","first-page":"1","volume":"78","author":"S Akira","year":"2001","unstructured":"Akira S (2001) Toll-like receptors and innate immunity. Adv Immunol 78:1\u201356","journal-title":"Adv Immunol"},{"key":"5574_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110138","volume":"118","author":"GA Albalawi","year":"2023","unstructured":"Albalawi GA, Albalawi MZ, Alsubaie KT, Albalawi AZ, Elewa MAF, Hashem KS, Al-Gayyar MMH (2023) Curative effects of crocin in ulcerative colitis via modulating apoptosis and inflammation. Int Immunopharmacol 118:110138","journal-title":"Int Immunopharmacol"},{"key":"5574_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105884","volume":"76","author":"K Amirshahrokhi","year":"2019","unstructured":"Amirshahrokhi K (2019) Febuxostat attenuates ulcerative colitis by the inhibition of NF-\u03baB, proinflammatory cytokines, and oxidative stress in mice. Int Immunopharmacol 76:105884","journal-title":"Int Immunopharmacol"},{"key":"5574_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110165","volume":"119","author":"K Amirshahrokhi","year":"2023","unstructured":"Amirshahrokhi K, Imani M (2023) Levetiracetam attenuates experimental ulcerative colitis through promoting Nrf2\/HO-1 antioxidant and inhibiting NF-\u03baB, proinflammatory cytokines and iNOS\/NO pathways. Int Immunopharmacol 119:110165","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"5574_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/ng.764","volume":"43","author":"CA Anderson","year":"2011","unstructured":"Anderson CA, Boucher G, Lees CW, Franke A, D\u2019Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagac\u00e9 C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, B\u00fcning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, L\u00e9mann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, Peyrin-Biroulet L, Pan\u00e9s J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms LA, Seielstad M, Steinhart AH, Targan SR, van den Berg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcinskas L, Sventoraityte J, Mansfield JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotter JI, Mathew CG, Griffiths AM, Gearry R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD (2011) Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43(3):246\u2013252","journal-title":"Nat Genet"},{"issue":"3","key":"5574_CR9","volume":"11","author":"MN Ansari","year":"2021","unstructured":"Ansari MN, Rehman NU, Karim A, Soliman GA, Ganaie MA, Raish M, Hamad AM (2021) Role of oxidative stress and inflammatory cytokines (TNF-\u03b1 and IL-6) in acetic acid-induced ulcerative colitis in rats: ameliorated by Otostegia fruticosa. Life (Basel) 11(3):195","journal-title":"Life (Basel)"},{"issue":"1","key":"5574_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4236\/pp.2016.71002","volume":"7","author":"EE Ashry","year":"2016","unstructured":"Ashry EE, Abdellatief RB, Mohamed AE, Kotb HI (2016) Protective effect of ketamine against acetic acid-induced ulcerative colitis in rats. Pharmacol Pharm 7(1):9","journal-title":"Pharmacol Pharm"},{"issue":"3","key":"5574_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.7762\/cnr.2020.9.3.223","volume":"9","author":"G Bahrami","year":"2020","unstructured":"Bahrami G, Malekshahi H, Miraghaee S, Madani H, Babaei A, Mohammadi B, Hatami R (2020) Protective and therapeutic effects of aloe vera gel on ulcerative colitis induced by acetic acid in rats. Clin Nutr Res 9(3):223","journal-title":"Clin Nutr Res"},{"issue":"1","key":"5574_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1476-5381.2010.01199.x","volume":"163","author":"P Barnes","year":"2011","unstructured":"Barnes P (2011) Glucocorticosteroids: current and future directions. Br J Pharmacol 163(1):29\u201343","journal-title":"Br J Pharmacol"},{"issue":"4","key":"5574_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/ajg.2015.52","volume":"110","author":"E Benchimol","year":"2015","unstructured":"Benchimol E, Mack D, Nguyen G (2015) Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study. Am J Gastroenterol 110(4):553\u2013563","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"5574_CR14","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/oxfordjournals.aje.a009735","volume":"149","author":"C Bernstein","year":"1999","unstructured":"Bernstein C, Blanchard J, Rawsthorne P, Wajda A (1999) Epidemiology of Crohn\u2019s disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 149(10):916\u2013924","journal-title":"Am J Epidemiol"},{"key":"5574_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.biopha.2016.11.080","volume":"85","author":"GB Bezerra","year":"2017","unstructured":"Bezerra GB, de Souza L, Dos Santos AS, de Almeida GKM, Souza MTS, Santos SL, Camargo EA, dos Santos Lima B, de Souza Ara\u00fajo AA, Cardoso JC (2017) Hydroalcoholic extract of Brazilian red propolis exerts protective effects on acetic acid-induced ulcerative colitis in a rodent model. Biomed Pharmacother 85:687\u201396","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"5574_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1152\/physrev.00040.2012","volume":"94","author":"A Bhattacharyya","year":"2014","unstructured":"Bhattacharyya A, Chattopadhyay R, Mitra S (2014) Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev 94(2):329\u2013354","journal-title":"Physiol Rev"},{"issue":"8","key":"5574_CR17","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1111\/j.1572-0241.2000.02263.x","volume":"95","author":"G Bonner","year":"2000","unstructured":"Bonner G, Walczak M, Royal D (2000) Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 95(8):1946\u20131948","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"5574_CR18","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","volume":"56","author":"K Boonstra","year":"2012","unstructured":"Boonstra K, Beuers U, Ponsioen C (2012) Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 56(5):1181\u20138","journal-title":"J Hepatol"},{"issue":"1","key":"5574_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ibd.21385","volume":"17","author":"S Brant","year":"2011","unstructured":"Brant S (2011) Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflamm Bowel Dis 17(1):1\u20135","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"5574_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/nu2030355","volume":"2","author":"P Calder","year":"2010","unstructured":"Calder P (2010) Omega-3 fatty acids and inflammatory processes. Nutrients 2(3):355\u2013374","journal-title":"Nutrients"},{"issue":"50","key":"5574_CR21","doi-asserted-by":"publisher","first-page":"13133","DOI":"10.1021\/acs.jafc.8b03942","volume":"66","author":"H Cao","year":"2018","unstructured":"Cao H, Liu J, Shen P, Cai J, Han Y, Zhu K, Fu Y, Zhang N, Zhang Z, Cao Y (2018) Protective effect of naringin on DSS-induced ulcerative colitis in mice. J Agric Food Chem 66(50):13133\u201340","journal-title":"J Agric Food Chem"},{"key":"5574_CR22","doi-asserted-by":"publisher","first-page":"15.25.1","DOI":"10.1002\/0471142735.im1525s104","volume":"104","author":"B Chassaing","year":"2014","unstructured":"Chassaing B, Aitken J, Malleshappa M, Vijay-Kumar M (2014) Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol 104:15.25.1\u2013.14","journal-title":"Curr Protoc Immunol"},{"issue":"5","key":"5574_CR23","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/apt.13700","volume":"44","author":"V Chhaya","year":"2016","unstructured":"Chhaya V, Saxena S, Cecil E, Subramanian V, Curcin V, Majeed A, Pollok R (2016) Steroid dependency and trends in prescribing for inflammatory bowel disease\u2013a 20\u2010year national population\u2010based study. Aliment Pharmacol Ther 44(5):482\u201394","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"5574_CR24","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1038\/s41598-025-86823-0","volume":"15","author":"M Cui","year":"2025","unstructured":"Cui M, Yang W-M, Yao P (2025) Protective effect of low-dose lactulose in dextran sulfate sodium induced ulcerative colitis model of rats. Sci Rep 15(1):2760","journal-title":"Sci Rep"},{"issue":"Supplement_1","key":"5574_CR25","doi-asserted-by":"publisher","first-page":"i091","DOI":"10.1093\/ecco-jcc\/jjab232.081","volume":"16","author":"S Danese","year":"2022","unstructured":"Danese S, Panaccione R, D\u2019Haens G, Peyrin-Biroulet L, Schreiber S, Kobayashi T, Gawdis-Wojnarska B, Korga P, Aguilar H, Sharkey B (2022) DOP42 Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active ulcerative colitis: 12-week results from the phase 2 LATTICE-UC study. J Crohns Colitis 16(Supplement_1):i091\u2013i2","journal-title":"J Crohns Colitis"},{"issue":"11","key":"5574_CR26","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1016\/j.cgh.2019.12.032","volume":"18","author":"S Danese","year":"2020","unstructured":"Danese S, Neurath MF, Kopo\u0144 A, Zakko SF, Simmons TC, Fogel R, Siegel CA, Panaccione R, Zhan X, Usiskin K, Chitkara D (2020) Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis. Clin Gastroenterol Hepatol 18(11):2526\u201334.e9","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10341","key":"5574_CR27","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W (2022) Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre trials. Lancet 399(10341):2113\u20132128","journal-title":"Lancet"},{"issue":"1","key":"5574_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1186\/s12876-023-03078-7","volume":"23","author":"S Danese","year":"2023","unstructured":"Danese S, Beaton A, Duncan EA, Mercier AK, Neisen J, Seth H, Zetterstrand S, Sands BE (2023) Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn\u2019s disease. BMC Gastroenterol 23(1):451","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"5574_CR29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/ng.3760","volume":"49","author":"K de Lange","year":"2017","unstructured":"de Lange K, Moutsianas L, Lee J (2017) Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet 49(2):256\u2013261","journal-title":"Nat Genet"},{"issue":"6","key":"5574_CR30","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1053\/gast.2001.23983","volume":"120","author":"G D\u2019Haens","year":"2001","unstructured":"D\u2019Haens G, Lemmens L, Geboes K (2001) Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120(6):1323\u20131329","journal-title":"Gastroenterology"},{"issue":"12","key":"5574_CR31","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/ibd.22917","volume":"18","author":"G D\u2019Haens","year":"2012","unstructured":"D\u2019Haens G, Ferrante M, Vermeire S (2012) Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 18(12):2218\u20132224","journal-title":"Inflamm Bowel Dis"},{"issue":"26","key":"5574_CR32","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T (2023) Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 388(26):2444\u20132455","journal-title":"N Engl J Med"},{"issue":"10","key":"5574_CR33","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.crohns.2012.09.003","volume":"6","author":"A Dignass","year":"2012","unstructured":"Dignass A, Eliakim R, Magro F (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 6(10):965\u2013990","journal-title":"J Crohns Colitis"},{"issue":"4","key":"5574_CR34","first-page":"1","volume":"40","author":"P Dulai","year":"2014","unstructured":"Dulai P, Siegel C, Colombel J, Sandborn W, Peyrin-Biroulet L (2014) Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy for remission induction in Crohn\u2019s disease. Aliment Pharmacol Ther 40(4):1\u20139","journal-title":"Aliment Pharmacol Ther"},{"issue":"45","key":"5574_CR35","doi-asserted-by":"publisher","first-page":"26448","DOI":"10.1074\/jbc.274.37.26448","volume":"274","author":"L Egan","year":"1999","unstructured":"Egan L, Mays D, Huntoon C (1999) Inhibition of interleukin-1-stimulated NF-kappaB RelA\/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 274(45):26448\u201326453","journal-title":"J Biol Chem"},{"key":"5574_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110309","volume":"120","author":"M Ekhtiar","year":"2023","unstructured":"Ekhtiar M, Ghasemi-Dehnoo M, Mirzaei Y, Azadegan-Dehkordi F, Amini-Khoei H, Lorigooini Z, Samiei-Sefat A, Bagheri N (2023) The coumaric acid and syringic acid ameliorate acetic acid-induced ulcerative colitis in rats via modulator of Nrf2\/HO-1 and pro-inflammatory cytokines. Int Immunopharmacol 120:110309","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"5574_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/08923973.2015.1021357","volume":"37","author":"EM El Morsy","year":"2015","unstructured":"El Morsy EM, Kamel R, Ahmed MA (2015) Attenuating effects of coenzyme Q10 and amlodipine in ulcerative colitis model in rats. Immunopharmacol Immunotoxicol 37(3):244\u201351","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"5574_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121187","volume":"311","author":"HMIA El-Fadl","year":"2022","unstructured":"El-Fadl HMIA, Mohamed MF (2022) Targeting endoplasmic reticulum stress, Nrf-2\/HO-1, and NF-\u03baB by myristicin and its role in attenuation of ulcerative colitis in rats. Life Sci 311:121187","journal-title":"Life Sci"},{"issue":"3","key":"5574_CR39","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/hep.25977","volume":"58","author":"D Ellinghaus","year":"2013","unstructured":"Ellinghaus D, Folseraas T, Holm K (2013) Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology 58(3):1074\u201383","journal-title":"Hepatology"},{"issue":"4","key":"5574_CR40","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/0016-5085(95)90599-5","volume":"109","author":"C Elson","year":"1995","unstructured":"Elson C, Sartor R, Tennyson G, Riddell R (1995) Experimental models of inflammatory bowel disease. Gastroenterology 109(4):1344\u20131367","journal-title":"Gastroenterology"},{"issue":"5","key":"5574_CR41","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.4049\/jimmunol.157.5.2174","volume":"157","author":"C Elson","year":"1996","unstructured":"Elson C, Beagley K, Sharmanov A (1996) Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol 157(5):2174\u20132185","journal-title":"J Immunol"},{"issue":"4","key":"5574_CR42","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s10787-022-01016-9","volume":"30","author":"GS El-Tanbouly","year":"2022","unstructured":"El-Tanbouly GS, Abdelrahman RS (2022) The emerging coloprotective effect of sildenafil against ulcerative colitis in rats via exerting counterbalance between NF-\u03baB signaling and Nrf-2\/HO-1 pathway. Inflammopharmacology 30(4):1351\u20131362","journal-title":"Inflammopharmacology"},{"issue":"1","key":"5574_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14420-6","volume":"12","author":"M Eskandari","year":"2022","unstructured":"Eskandari M, Asgharzadeh F, Askarnia-Faal MM, Naimi H, Avan A, Ahadi M, Vossoughinia H, Gharib M, Soleimani A, Naghibzadeh N (2022) Mebendazole, an anti-helminth drug, suppresses inflammation, oxidative stress and injury in a mouse model of ulcerative colitis. Sci Rep 12(1):10249","journal-title":"Sci Rep"},{"issue":"6","key":"5574_CR44","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s10787-018-0538-1","volume":"26","author":"N Fakhraei","year":"2018","unstructured":"Fakhraei N, Javadian N, Rahimian R, Nili F, Rahimi N, Hashemizadeh S, Dehpour AR (2018) Involvement of central opioid receptors in protective effects of methadone on experimental colitis in rats. Inflammopharmacology 26(6):1399\u2013413","journal-title":"Inflammopharmacology"},{"issue":"4","key":"5574_CR45","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/ddr.21256","volume":"76","author":"AJ Fatani","year":"2015","unstructured":"Fatani AJ, Al\u2010Hosaini KA, Ahmed MM, Abuohashish HM, Parmar MY, Al\u2010Rejaie SS (2015) Carvedilol attenuates inflammatory biomarkers and oxidative stress in a rat model of ulcerative colitis. Drug Dev Res 76(4):204\u201314","journal-title":"Drug Dev Res"},{"issue":"Suppl","key":"5574_CR46","first-page":"125","volume":"15","author":"E Fattahian","year":"2016","unstructured":"Fattahian E, Hajhashemi V, Rabbani M, Minaiyan M, Mahzouni P (2016) Anti-inflammatory effect of amitriptyline on ulcerative colitis in normal and reserpine-induced depressed rats. Iran J Pharm Res: IJPR 15(Suppl):125","journal-title":"Iranian Journal of Pharmaceutical Research: IJPR"},{"issue":"8","key":"5574_CR47","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, Van Assche G, Axler J, Kim H-J, Danese S (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369(8):699\u2013710","journal-title":"N Engl J Med"},{"issue":"11","key":"5574_CR48","first-page":"4063","volume":"7","author":"J Feng","year":"2014","unstructured":"Feng J, Guo C, Zhu Y, Pang L, Yang Z, Zou Y, Zheng X (2014) Baicalin down regulates the expression of TLR4 and NFkB-p65 in colon tissue in mice with colitis induced by dextran sulfate sodium. Int J Clin Exp Med 7(11):4063\u20134072","journal-title":"Int J Clin Exp Med"},{"key":"5574_CR49","doi-asserted-by":"crossref","unstructured":"Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clinic Proceedings: Elsevier, 2014. pp. 1553\u201363.","DOI":"10.1016\/j.mayocp.2014.07.002"},{"issue":"5","key":"5574_CR50","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"J Feuerstein","year":"2020","unstructured":"Feuerstein J, Isaacs K, Schneider Y (2020) AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology 158(5):1450\u20131461","journal-title":"Gastroenterology"},{"issue":"3","key":"5574_CR51","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/gut.47.3.404","volume":"47","author":"K Geboes","year":"2000","unstructured":"Geboes K, Riddell R, Ost A (2000) A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47(3):404\u2013409","journal-title":"Gut"},{"key":"5574_CR52","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.biopha.2017.03.038","volume":"90","author":"M Ghasemi-Pirbaluti","year":"2017","unstructured":"Ghasemi-Pirbaluti M, Motaghi E, Najafi A, Hosseini MJ (2017) The effect of theophylline on acetic acid induced ulcerative colitis in rats. Biomed Pharmacother 90:153\u20139","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5574_CR53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomollon","year":"2016","unstructured":"Gomollon F, Dignass A, Annese V (2016) 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11(1):3\u201325","journal-title":"J Crohns Colitis"},{"key":"5574_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108174","volume":"101","author":"HM Hafez","year":"2021","unstructured":"Hafez HM, Ibrahim MA, Abdelzaher WY, Gad AA, Hafez SMNA, Abdel-Gaber SA (2021) Protective effect of mirtazapine against acetic acid-induced ulcerative colitis in rats: role of NLRP3 inflammasome pathway. Int Immunopharmacol 101:108174","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"5574_CR55","volume":"2","author":"J Hasskamp","year":"2025","unstructured":"Hasskamp J, Meinhardt C, Patton PH, Timmer A (2025) Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2(2):Cd000478","journal-title":"Cochrane Database Syst Rev"},{"issue":"23","key":"5574_CR56","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1001\/jama.2015.16700","volume":"314","author":"C Hawkey","year":"2015","unstructured":"Hawkey C, Allez M, Clark M (2015) Autologous hematopoietic stem cell transplantation for refractory Crohn\u2019s disease. JAMA 314(23):2524\u20132534","journal-title":"JAMA"},{"issue":"2","key":"5574_CR57","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","volume":"129","author":"F Heller","year":"2005","unstructured":"Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, B\u00fcrgel N, Fromm M (2005) Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129(2):550\u2013564","journal-title":"Gastroenterology"},{"issue":"8","key":"5574_CR58","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1097\/JOM.0b013e31816fd663","volume":"50","author":"E Hillson","year":"2008","unstructured":"Hillson E, Dybicz S, Waters HC, Stuart B, Schaneman J, Dabbous O, Erwin WG, Kersh A, Broussard D (2008) Health care expenditures in ulcerative colitis: the perspective of a self-insured employer. J Occup Environ Med 50(8):969\u2013977","journal-title":"J Occup Environ Med"},{"issue":"4","key":"5574_CR59","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/jpp\/rgab170","volume":"74","author":"MA Ibrahim","year":"2022","unstructured":"Ibrahim MA, Abdelmonaem AA, Abdel-Gaber SA, Hafez HM, Abdel Hafez SMN, Yehia Abdelzaher W (2022) Rupatadine ameliorated ulcerative colitis in rats via modulation of platelet-activatiweng factor\/interleukin-6\/vascular endothelial growth factor signalling pathway. J Pharm Pharmacol 74(4):537\u201346","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"5574_CR60","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","volume":"106","author":"E Irvine","year":"1994","unstructured":"Irvine E, Feagan B, Rochon J (1994) Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 106(2):287\u2013296","journal-title":"Gastroenterology"},{"issue":"4","key":"5574_CR61","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s10735-025-10527-y","volume":"56","author":"FR Jaafar","year":"2025","unstructured":"Jaafar FR, Attarbashee RK, Abu-Raghif AR, Ridha-Salman H (2025) Gemifloxacin ameliorates acetic acid-induced ulcerative colitis via modulation of inflammatory, oxidative, and adhesive biomarkers and histopathological changes in rats. J Mol Histol 56(4):250","journal-title":"J Mol Histol"},{"issue":"12","key":"5574_CR62","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.3748\/wjg.v11.i12.1747","volume":"11","author":"YT Jian","year":"2005","unstructured":"Jian YT, Mai GF, Wang JD, Zhang YL, Luo RC, Fang YX (2005) Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 11(12):1747\u20131752","journal-title":"World J Gastroenterol"},{"issue":"7422","key":"5574_CR63","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins L, Ripke S, Weersma R (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491(7422):119\u2013124","journal-title":"Nature"},{"issue":"2","key":"5574_CR64","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.vascn.2003.12.002","volume":"50","author":"A Jurjus","year":"2004","unstructured":"Jurjus A, Khoury N, Reimund J (2004) Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 50(2):81\u201392","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"1","key":"5574_CR65","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","volume":"18","author":"G Kaplan","year":"2021","unstructured":"Kaplan G, Windsor J (2021) The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 18(1):56\u201366","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"5574_CR66","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/gut.2007.121467","volume":"56","author":"G Kaplan","year":"2007","unstructured":"Kaplan G, Pedersen B, Andersson R (2007) The risk of developing Crohn\u2019s disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut 56(10):1387\u201392","journal-title":"Gut"},{"issue":"3","key":"5574_CR67","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/ibd\/izac095","volume":"29","author":"K Kawashima","year":"2023","unstructured":"Kawashima K, Oshima N, Kishimoto K, Kataoka M, Fukunaga M, Kotani S, Sonoyama H, Oka A, Mishima Y, Kazumori H (2023) Low fecal calprotectin predicts histological healing in patients with ulcerative colitis with endoscopic remission and leads to prolonged clinical remission. Inflamm Bowel Dis 29(3):359\u201366","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"5574_CR68","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-018-0022-9","volume":"15","author":"H Khalili","year":"2018","unstructured":"Khalili H, Chan S, Lochhead P (2018) The role of diet in the aetiopathogenesis of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 15(9):525\u2013535","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"5574_CR69","first-page":"1428","volume":"28","author":"K Kharazmi","year":"2025","unstructured":"Kharazmi K, Nazari SE, Eskandari M, Asgharzadeh F, Aminian A, Avan A, Hassanian SM, Khazaei M (2025) Repurposing Artrestan (sacubitril\/valsartan), unveiling its anti-inflammatory and fibrinolytic properties in ulcerative colitis in rats. Iran J Basic Med Sci 28(10):1428","journal-title":"Iran J Basic Med Sci"},{"issue":"2","key":"5574_CR70","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jcmgh.2015.01.006","volume":"1","author":"P Kiesler","year":"2015","unstructured":"Kiesler P, Fuss I, Strober W (2015) Experimental models of inflammatory bowel diseases. Cell Mol Gastroenterol Hepatol 1(2):154\u2013170","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"2","key":"5574_CR71","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/ibd\/izad061","volume":"30","author":"Y Kilic","year":"2024","unstructured":"Kilic Y, Kamal S, Jaffar F, Sriranganathan D, Quraishi MN, Segal JP (2024) Prevalence of extraintestinal manifestations in inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 30(2):230\u20139","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"5574_CR72","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ibd\/izx100","volume":"24","author":"S Knowles","year":"2018","unstructured":"Knowles S, Graff L, Wilding H (2018) Quality of life in inflammatory bowel disease: a systematic review and meta-analyses part I. Inflamm Bowel Dis 24(4):742\u201351","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"5574_CR73","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/1744666X.2022.2074401","volume":"18","author":"G Kokkotis","year":"2022","unstructured":"Kokkotis G, Bamias G (2022) TL1A as a therapeutic target in inflammatory bowel disease. Expert Rev Clin Immunol 18(6):551\u20135","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"5574_CR74","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1365-2567.2004.01984.x","volume":"113","author":"G Kolios","year":"2004","unstructured":"Kolios G, Valatas V, Ward S (2004) Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 113(4):427\u2013437","journal-title":"Immunology"},{"issue":"4","key":"5574_CR75","doi-asserted-by":"publisher","first-page":"e794","DOI":"10.1542\/peds.2011-3886","volume":"130","author":"M Kronman","year":"2012","unstructured":"Kronman M, Zaoutis T, Haynes K (2012) Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 130(4):e794\u2013803","journal-title":"Pediatrics"},{"issue":"8","key":"5574_CR76","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3748\/wjg.v17.i8.976","volume":"17","author":"H-K Kwon","year":"2011","unstructured":"Kwon H-K, Hwang J-S, Lee C-G, So J-S, Sahoo A, Im C-R, Jeon WK, Ko BS, Lee SH, Park ZY (2011) Cinnamon extract suppresses experimental colitis through modulation of antigen-presenting cells. World J Gastroenterol: WJG 17(8):976","journal-title":"World J Gastroenterol: WJG"},{"issue":"8","key":"5574_CR77","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3748\/wjg.v17.i8.976","volume":"17","author":"HK Kwon","year":"2011","unstructured":"Kwon HK, Hwang JS, Lee CG, So JS, Sahoo A, Im CR, Jeon WK, Ko BS, Lee SH, Park ZY, Im SH (2011) Cinnamon extract suppresses experimental colitis through modulation of antigen-presenting cells. World J Gastroenterol 17(8):976\u2013986","journal-title":"World J Gastroenterol"},{"issue":"32","key":"5574_CR78","doi-asserted-by":"publisher","first-page":"385","DOI":"10.5897\/AJPP2017.4820","volume":"11","author":"DAA Labib","year":"2017","unstructured":"Labib DAA, Abdelzaher WY, Shaker OG, Elfarouk LO (2017) Evaluation of the colo-protective effects of tadalafil in an experimental model of ulcerative colitis in rats. Afr J Pharm Pharmacol 11(32):385\u201393","journal-title":"Afr J Pharm Pharmacol"},{"issue":"2","key":"5574_CR79","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/gut.51.2.143","volume":"51","author":"L Lennard","year":"2002","unstructured":"Lennard L (2002) TPMT in the treatment of Crohn\u2019s disease with azathioprine. Gut 51(2):143\u2013146","journal-title":"Gut"},{"issue":"1","key":"5574_CR80","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.gastro.2011.04.011","volume":"141","author":"P Lepage","year":"2011","unstructured":"Lepage P, Hasler R, Spehlmann M (2011) Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 141(1):227\u2013236","journal-title":"Gastroenterology"},{"issue":"6","key":"5574_CR81","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.autrev.2015.01.009","volume":"14","author":"A Lerner","year":"2015","unstructured":"Lerner A, Matthias T (2015) Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun Rev 14(6):479\u2013489","journal-title":"Autoimmun Rev"},{"key":"5574_CR82","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.mib.2016.10.003","volume":"35","author":"M Levy","year":"2017","unstructured":"Levy M, Blacher E, Elinav E (2017) Microbiome, metabolites and host immunity. Curr Opin Microbiol 35:8\u201315","journal-title":"Curr Opin Microbiol"},{"issue":"12","key":"5574_CR83","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ibd.20520","volume":"14","author":"J Lewis","year":"2008","unstructured":"Lewis J, Chuai S, Nessel L (2008) Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 14(12):1660\u20131666","journal-title":"Inflamm Bowel Dis"},{"key":"5574_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.119008","volume":"269","author":"B Li","year":"2021","unstructured":"Li B, Du P, Du Y, Zhao D, Cai Y, Yang Q, Guo Z (2021) Luteolin alleviates inflammation and modulates gut microbiota in ulcerative colitis rats. Life Sci 269:119008","journal-title":"Life Sci"},{"key":"5574_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154321","volume":"104","author":"X Li","year":"2022","unstructured":"Li X, Wu X, Wang Q, Xu W, Zhao Q, Xu N, Hu X, Ye Z, Yu S, Liu J (2022) Sanguinarine ameliorates DSS induced ulcerative colitis by inhibiting NLRP3 inflammasome activation and modulating intestinal microbiota in C57BL\/6 mice. Phytomedicine 104:154321","journal-title":"Phytomedicine"},{"issue":"1","key":"5574_CR86","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1021\/acsomega.3c07474","volume":"9","author":"W-Y Li","year":"2023","unstructured":"Li W-Y, Liu J-Y, Wang Z-X, Wang K-Y, Huang C-X, He W, Song J-L (2023) Sinapic acid attenuates chronic DSS-induced intestinal fibrosis in C57bl\/6J mice by modulating NLRP3 inflammasome activation and the autophagy pathway. ACS Omega 9(1):1230\u201341","journal-title":"ACS Omega"},{"issue":"2","key":"5574_CR87","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.intimp.2015.02.016","volume":"25","author":"S-M Lim","year":"2015","unstructured":"Lim S-M, Jeong J-J, Kang G-D, Kim K-A, Choi H-S, Kim D-H (2015) Timosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-\u03baB and MAPK activation and restoring Th17\/Treg cell balance. Int Immunopharmacol 25(2):493\u2013503","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"5574_CR88","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1016\/j.apsb.2020.11.003","volume":"11","author":"P Liu","year":"2021","unstructured":"Liu P, Gao C, Chen H, Vong CT, Wu X, Tang X, Wang S, Wang Y (2021) Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: opportunities and emerging strategies. Acta Pharm Sin B 11(9):2798\u2013818","journal-title":"Acta Pharm Sin B"},{"issue":"7758","key":"5574_CR89","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","volume":"569","author":"J Lloyd-Price","year":"2019","unstructured":"Lloyd-Price J, Arze C, Ananthakrishnan A (2019) Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569(7758):655\u2013662","journal-title":"Nature"},{"issue":"6","key":"5574_CR90","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","volume":"126","author":"EJ Loftus","year":"2004","unstructured":"Loftus EJ (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126(6):1504\u20131517","journal-title":"Gastroenterology"},{"key":"5574_CR91","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fimmu.2013.00181","volume":"4","author":"L Lopetuso","year":"2013","unstructured":"Lopetuso L, Chowdhry S, Pizarro T (2013) Opposing functions of classic and novel IL-1 family members in gut health and disease. Front Immunol 4:181","journal-title":"Front Immunol"},{"issue":"10S","key":"5574_CR92","doi-asserted-by":"publisher","first-page":"S624","DOI":"10.14309\/01.ajg.0000953020.05891.05","volume":"118","author":"E Louis","year":"2023","unstructured":"Louis E, Panaccione R, Parkes G, Peyrin-Biroulet L, Ferrante M, Takeuchi K, Siegmund B, Levine P, Kalabic J, Neimark E (2023) S845 Risankizumab induction therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized phase 3 INSPIRE study. Am J Gastroenterol 118(10S):S624","journal-title":"Am J Gastroenterol"},{"issue":"11\u201312","key":"5574_CR93","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/apt.12086","volume":"36","author":"P Lunney","year":"2012","unstructured":"Lunney P, Leong R (2012) Review article: ulcerative colitis, smoking and nicotine therapy. Aliment Pharmacol Ther 36(11\u201312):997\u20131008","journal-title":"Aliment Pharmacol Ther"},{"key":"5574_CR94","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3389\/fphar.2018.00944","volume":"9","author":"X Ma","year":"2018","unstructured":"Ma X, Hu Y, Li X, Zheng X, Wang Y, Zhang J, Fu C, Geng F (2018) Periplaneta americana ameliorates dextran sulfate sodium-induced ulcerative colitis in rats by Keap1\/Nrf-2 activation, intestinal barrier function, and gut microbiota regulation. Front Pharmacol 9:944","journal-title":"Front Pharmacol"},{"issue":"2","key":"5574_CR95","first-page":"135","volume":"17","author":"B MacPherson","year":"1978","unstructured":"MacPherson B, Pfeiffer C (1978) Experimental production of diffuse colitis in rats. Digestion 17(2):135\u2013150","journal-title":"Digestion"},{"issue":"5","key":"5574_CR96","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1007\/s00210-024-03631-5","volume":"398","author":"RNE Mahdy","year":"2025","unstructured":"Mahdy RNE, Nader MA, Helal MG, Abu-Risha SE, Abdelmageed ME (2025) Protective effect of dulaglutide, a GLP1 agonist, on acetic acid-induced ulcerative colitis in rats: involvement of GLP-1, TFF-3, and TGF-\u03b2\/PI3K\/NF-\u03baB signaling pathway. Naunyn Schmiedebergs Arch Pharmacol 398(5):5611\u201328","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"5574_CR97","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/jgh.14872","volume":"35","author":"W Mak","year":"2020","unstructured":"Mak W, Zhao M, Ng S, Burisch J (2020) The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol 35(3):380\u2013389","journal-title":"J Gastroenterol Hepatol"},{"issue":"7351","key":"5574_CR98","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10208","volume":"474","author":"KJ Maloy","year":"2011","unstructured":"Maloy KJ, Powrie F (2011) Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474(7351):298\u2013306","journal-title":"Nature"},{"issue":"1","key":"5574_CR99","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4103\/0974-8520.168998","volume":"36","author":"BA Mannasaheb","year":"2015","unstructured":"Mannasaheb BA, Kulkarni PV, Sangreskopp MA, Savant C, Mohan A (2015) Protective effect of Agave americana Linn. leaf extract in acetic acid-induced ulcerative colitis in rats. AYU (An International Quarterly Journal of Research in Ayurveda) 36(1):101\u20136","journal-title":"AYU (An International Quarterly Journal of Research in Ayurveda)"},{"issue":"1","key":"5574_CR100","volume":"2012","author":"J-W Mao","year":"2012","unstructured":"Mao J-W, Tang H-Y, Wang Y-D (2012) Influence of rosiglitazone on the expression of ppar\u03b3, nf\u2010\u03bab, and tnf\u2010\u03b1 in rat model of ulcerative colitis. Gastroenterol Res Pract 2012(1):845672","journal-title":"Gastroenterol Res Pract"},{"issue":"4","key":"5574_CR101","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10787-015-0234-3","volume":"23","author":"MM Mathew","year":"2015","unstructured":"Mathew MM, Han NV, Murugesan A, Raj EA, Prasanth KG (2015) Evaluation of the protective effect of Pterocarpus marsupium on acetic acid-induced ulcerative colitis in rats. Inflammopharmacology 23(4):195\u2013201","journal-title":"Inflammopharmacology"},{"issue":"7","key":"5574_CR102","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1053\/j.gastro.2005.03.043","volume":"128","author":"J Maul","year":"2005","unstructured":"Maul J, Loddenkemper C, Mundt P (2005) Peripheral and intestinal regulatory CD4+ CD25high T cells in inflammatory bowel disease. Gastroenterology 128(7):1868\u201378","journal-title":"Gastroenterology"},{"issue":"10","key":"5574_CR103","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1136\/gut.2005.064261","volume":"54","author":"J Mawdsley","year":"2005","unstructured":"Mawdsley J, Rampton D (2005) Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 54(10):1481\u20131491","journal-title":"Gut"},{"issue":"3","key":"5574_CR104","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1172\/JCI76304","volume":"125","author":"E Mayer","year":"2015","unstructured":"Mayer E, Tillisch K, Gupta A (2015) Gut\/brain axis and the microbiota. J Clin Invest 125(3):926\u2013938","journal-title":"J Clin Invest"},{"key":"5574_CR105","doi-asserted-by":"publisher","first-page":"1725084","DOI":"10.3389\/fimmu.2025.1725084","volume":"16","author":"G Miao","year":"2025","unstructured":"Miao G, Zhang D, Sui Z, Leng J, Deng Y, Gu X, Cao H (2025) Berberine-taxifolin co-administration attenuates inflammatory response and intestinal barrier injury via nf-\u03baB\/NLRP3 suppression in colitis. Front Immunol 16:1725084","journal-title":"Front Immunol"},{"issue":"1","key":"5574_CR106","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","volume":"149","author":"P Moayyedi","year":"2015","unstructured":"Moayyedi P, Surette M, Kim P (2015) Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149(1):102\u2013109","journal-title":"Gastroenterology"},{"issue":"12","key":"5574_CR107","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","volume":"372","author":"G Monteleone","year":"2015","unstructured":"Monteleone G, Neurath M, Ardizzone S (2015) Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn\u2019s disease. N Engl J Med 372(12):1104\u20131113","journal-title":"N Engl J Med"},{"issue":"3","key":"5574_CR108","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/0016-5085(89)90904-9","volume":"96","author":"G Morris","year":"1989","unstructured":"Morris G, Beck P, Herridge M (1989) Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96(3):795\u2013803","journal-title":"Gastroenterology"},{"issue":"4","key":"5574_CR109","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/jpp\/rgad013","volume":"75","author":"RE Mostafa","year":"2023","unstructured":"Mostafa RE, Abdel-Rahman RF (2023) Ezetimibe alleviates acetic acid-induced ulcerative colitis in rats: targeting the Akt\/NF-\u03baB\/STAT3\/CXCL10 signaling axis. J Pharm Pharmacol 75(4):533\u201343","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"5574_CR110","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1007\/s11033-021-06357-2","volume":"48","author":"A Motavallian","year":"2021","unstructured":"Motavallian A, Bouzari S, Zamani E, Karimian P, Dabirian S, Molavi M, Torshkooh FA (2021) An investigation of the anti-inflammatory effects of gabapentin on acetic acid-induced colitis in rats. Mol Biol Rep 48(4):3423\u201330","journal-title":"Mol Biol Rep"},{"issue":"7","key":"5574_CR111","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3390\/biomedicines10071695","volume":"10","author":"M Nakayama","year":"2022","unstructured":"Nakayama M, Ozato Y, Tsuji Y, Arao Y, Otsuka C, Hamano Y, Sumi G, Ofusa K, Uchida S, Vecchione A (2022) RNA modification in inflammatory bowel diseases. Biomedicines 10(7):1695","journal-title":"Biomedicines"},{"issue":"5","key":"5574_CR112","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri3661","volume":"14","author":"M Neurath","year":"2014","unstructured":"Neurath M (2014) Cytokines in inflammatory bowel disease. Nat Rev Immunol 14(5):329\u2013342","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"5574_CR113","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41590-019-0415-0","volume":"20","author":"M Neurath","year":"2019","unstructured":"Neurath M (2019) Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol 20(8):970\u20139","journal-title":"Nat Immunol"},{"issue":"5","key":"5574_CR114","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","volume":"182","author":"M Neurath","year":"1995","unstructured":"Neurath M, Fuss I, Kelsall B, Stuber E, Strober W (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182(5):1281\u20131290","journal-title":"J Exp Med"},{"issue":"10114","key":"5574_CR115","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"S Ng","year":"2017","unstructured":"Ng S, Shi H, Hamidi N (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390(10114):2769\u20132778","journal-title":"Lancet"},{"issue":"3","key":"5574_CR116","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/0016-5085(90)90290-H","volume":"98","author":"I Okayasu","year":"1990","unstructured":"Okayasu I, Hatakeyama S, Yamada M (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98(3):694\u2013702","journal-title":"Gastroenterology"},{"issue":"1","key":"5574_CR117","volume":"2020","author":"G Owusu","year":"2020","unstructured":"Owusu G, Obiri DD, Ainooson GK, Osafo N, Antwi AO, Duduyemi BM, Ansah C (2020) Acetic acid\u2010induced ulcerative colitis in Sprague Dawley rats is suppressed by hydroethanolic extract of Cordia vignei leaves through reduced serum levels of TNF\u2010\u03b1 and IL\u20106. Int J Chron Dis 2020(1):8785497","journal-title":"Int J Chron Dis"},{"issue":"1","key":"5574_CR118","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/1750-3841.15982","volume":"87","author":"L Pang","year":"2022","unstructured":"Pang L, Wang T, Liao Q, Cheng Y, Wang D, Li J, Fu C, Zhang C, Zhang J (2022) Protective role of ergothioneine isolated from Pleurotus ostreatus against dextran sulfate sodium\u2010induced ulcerative colitis in rat model. J Food Sci 87(1):415\u201326","journal-title":"J Food Sci"},{"issue":"10075","key":"5574_CR119","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","volume":"389","author":"S Paramsothy","year":"2017","unstructured":"Paramsothy S, Kamm M, Kaakoush N (2017) Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389(10075):1218\u20131228","journal-title":"Lancet"},{"issue":"3","key":"5574_CR120","first-page":"135","volume":"10","author":"A Pituch-Zdanowska","year":"2015","unstructured":"Pituch-Zdanowska A, Banaszkiewicz A, Albrecht P (2015) The role of dietary fibre in inflammatory bowel disease. Prz Gastroenterol 10(3):135\u2013141","journal-title":"Prz Gastroenterol"},{"issue":"1","key":"5574_CR121","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nm.4236","volume":"23","author":"H Plovier","year":"2017","unstructured":"Plovier H, Everard A, Druart C (2017) A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 23(1):107\u201313","journal-title":"Nat Med"},{"issue":"08","key":"5574_CR122","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1055\/a-1855-1491","volume":"72","author":"A Rashidian","year":"2022","unstructured":"Rashidian A, Mohammadi S, Hamaneh AM, Chaboki A, Shayan M, Sheibani M, Abdollahi A, Yousefi-Manesh H, Dehpour AR (2022) Buspirone ameliorates colon inflammation in TNBS-induced rat acute colitis: the involvement of TLR4\/NF-kB pathway. Drug Res (Stuttg) 72(08):449\u201356","journal-title":"Drug Res (Stuttg)"},{"key":"5574_CR123","doi-asserted-by":"publisher","DOI":"10.31661\/gmj.v8i0.1095","volume":"8","author":"N Rezaei","year":"2019","unstructured":"Rezaei N, Eftekhari MH, Tanideh N, Mokhtari M, Bagheri Z (2019) Comparison of antioxidant and anti-inflammatory effects of honey and spirulina platensis with sulfasalazine and mesalazine on acetic acid-induced ulcerative colitis in rats. Galen Med J 8:e1095","journal-title":"Galen Med J"},{"issue":"8","key":"5574_CR124","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1084\/jem.20041948","volume":"201","author":"C Rousseaux","year":"2005","unstructured":"Rousseaux C, Lefebvre B, Dubuquoy L (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201(8):1205\u20131215","journal-title":"J Exp Med"},{"issue":"23","key":"5574_CR125","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn W, Feagan B (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353(23):2462\u20132476","journal-title":"N Engl J Med"},{"key":"5574_CR126","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.taap.2018.12.020","volume":"364","author":"S Saber","year":"2019","unstructured":"Saber S, Khalil RM, Abdo WS, Nassif D, El-Ahwany E (2019) Olmesartan ameliorates chemically-induced ulcerative colitis in rats via modulating NF\u03baB and Nrf-2\/HO-1 signaling crosstalk. Toxicol Appl Pharmacol 364:120\u201332","journal-title":"Toxicol Appl Pharmacol"},{"key":"5574_CR127","first-page":"482","volume":"15","author":"SS Sadar","year":"2016","unstructured":"Sadar SS, Vyawahare NS, Bodhankar SL (2016) Ferulic acid ameliorates TNBS-induced ulcerative colitis through modulation of cytokines, oxidative stress, iNOs, COX-2, and apoptosis in laboratory rats. Excli J 15:482\u201399","journal-title":"Excli J"},{"issue":"10","key":"5574_CR128","first-page":"1867","volume":"92","author":"M Safdi","year":"1997","unstructured":"Safdi M, DeMicco M, Sninsky C (1997) A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92(10):1867\u20131871","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"5574_CR129","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.intimp.2013.09.022","volume":"17","author":"K Sakthivel","year":"2013","unstructured":"Sakthivel K, Guruvayoorappan C (2013) Amentoflavone inhibits iNOS, COX-2 expression and modulates cytokine profile, NF-\u03baB signal transduction pathways in rats with ulcerative colitis. Int Immunopharmacol 17(3):907\u201316","journal-title":"Int Immunopharmacol"},{"issue":"18","key":"5574_CR130","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"W Sandborn","year":"2005","unstructured":"Sandborn W, Colombel J, Enns R (2005) Natalizumab induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 353(18):1912\u20131925","journal-title":"N Engl J Med"},{"issue":"2","key":"5574_CR131","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"W Sandborn","year":"2012","unstructured":"Sandborn W, van Assche G, Reinisch W (2012) Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142(2):257\u2013265","journal-title":"Gastroenterology"},{"issue":"16","key":"5574_CR132","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","volume":"367","author":"W Sandborn","year":"2012","unstructured":"Sandborn W, Gasink C, Gao L (2012) Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease. N Engl J Med 367(16):1519\u20131528","journal-title":"N Engl J Med"},{"issue":"1","key":"5574_CR133","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","volume":"146","author":"W Sandborn","year":"2014","unstructured":"Sandborn W, Feagan B, Marano C (2014) Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146(1):85\u201395","journal-title":"Gastroenterology"},{"issue":"18","key":"5574_CR134","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"W Sandborn","year":"2017","unstructured":"Sandborn W, Su C, Sands B (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376(18):1723\u20131736","journal-title":"N Engl J Med"},{"issue":"2","key":"5574_CR135","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/ecco-jcc\/jjy149","volume":"13","author":"WJ Sandborn","year":"2019","unstructured":"Sandborn WJ, Colombel J-F, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K (2019) Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis. J Crohns Colitis 13(2):172\u201381","journal-title":"J Crohns Colitis"},{"issue":"14","key":"5574_CR136","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","volume":"385","author":"W Sandborn","year":"2021","unstructured":"Sandborn W, Feagan B, D\u2019Haens G (2021) Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med 385(14):1280\u20131291","journal-title":"N Engl J Med"},{"issue":"10383","key":"5574_CR137","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"W Sandborn","year":"2023","unstructured":"Sandborn W, Vermeire S, Peyrin-Biroulet L (2023) Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled trials. Lancet 401(10383):1159\u20131171","journal-title":"Lancet"},{"issue":"5","key":"5574_CR138","doi-asserted-by":"publisher","first-page":"738","DOI":"10.14309\/ajg.0000000000000493","volume":"115","author":"BE Sands","year":"2020","unstructured":"Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Colombel JF, Rossiter G, Usiskin K, Ather S, Zhan X (2020) Mongersen (GED-0301) for active Crohn\u2019s disease: results of a phase 3 study. Am J Gastroenterol 115(5):738\u201345","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"5574_CR139","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","volume":"153","author":"BE Sands","year":"2017","unstructured":"Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, Higgins PDR, Newbold P, Faggioni R, Patra K, Li J, Klekotka P, Morehouse C, Pulkstenis E, Drappa J, van der Merwe R, Gasser RA Jr (2017) Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn\u2019s disease: a phase 2a study. Gastroenterology 153(1):77\u201386.e6","journal-title":"Gastroenterology"},{"issue":"13","key":"5574_CR140","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"B Sands","year":"2019","unstructured":"Sands B, Sandborn W, Panaccione R (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381(13):1201\u20131214","journal-title":"N Engl J Med"},{"issue":"10","key":"5574_CR141","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/ibd\/izac200","volume":"29","author":"EHJ Savelkoul","year":"2023","unstructured":"Savelkoul EHJ, Thomas PWA, Derikx L, den Broeder N, R\u00f6mkens TEH, Hoentjen F (2023) Systematic review and meta-analysis: loss of response and need for dose escalation of infliximab and adalimumab in ulcerative colitis. Inflamm Bowel Dis 29(10):1633\u20131647","journal-title":"Inflamm Bowel Dis"},{"issue":"26","key":"5574_CR142","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"K Schroeder","year":"1987","unstructured":"Schroeder K, Tremaine W, Ilstrup D (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 317(26):1625\u20131629","journal-title":"N Engl J Med"},{"issue":"Suppl A","key":"5574_CR143","doi-asserted-by":"publisher","first-page":"5A","DOI":"10.1155\/2005\/269076","volume":"19","author":"M Silverberg","year":"2005","unstructured":"Silverberg M, Satsangi J, Ahmad T (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl A):5A\u201336A","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"5574_CR144","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/0016-5085(92)91112-H","volume":"103","author":"N Simmonds","year":"1992","unstructured":"Simmonds N, Allen R, Stevens T (1992) Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 103(1):186\u201396","journal-title":"Gastroenterology"},{"issue":"43","key":"5574_CR145","doi-asserted-by":"publisher","first-page":"16731","DOI":"10.1073\/pnas.0804812105","volume":"105","author":"H Sokol","year":"2008","unstructured":"Sokol H, Pigneur B, Watterlot L (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105(43):16731\u20136","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5574_CR146","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cbi.2018.11.002","volume":"298","author":"NA Soliman","year":"2019","unstructured":"Soliman NA, Keshk WA, Rizk FH, Ibrahim M (2019) The possible ameliorative effect of simvastatin versus sulfasalazine on acetic acid induced ulcerative colitis in adult rats. Chem Biol Interact 298:57\u201365","journal-title":"Chem Biol Interact"},{"key":"5574_CR147","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.biopha.2017.05.057","volume":"91","author":"JK Suluvoy","year":"2017","unstructured":"Suluvoy JK, Sakthivel K, Guruvayoorappan C, Grace VB (2017) Protective effect of Averrhoa bilimbi L. fruit extract on ulcerative colitis in wistar rats via regulation of inflammatory mediators and cytokines. Biomed Pharmacother 91:1113\u201321","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5574_CR148","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G (2020) ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis 14(1):4\u201322","journal-title":"J Crohns Colitis"},{"issue":"8","key":"5574_CR149","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/jcph.887","volume":"57","author":"J Tran","year":"2017","unstructured":"Tran J, Hartung J, Peach R (2017) Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator. J Clin Pharmacol 57(8):988\u2013996","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"5574_CR150","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/gutjnl-2011-300486","volume":"61","author":"S Travis","year":"2012","unstructured":"Travis S, Schnell D, Krzeski P (2012) Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 61(4):535\u2013542","journal-title":"Gut"},{"issue":"3","key":"5574_CR151","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","volume":"63","author":"S Travis","year":"2014","unstructured":"Travis S, Danese S, Kupcinskas L (2014) Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 63(3):433\u2013441","journal-title":"Gut"},{"issue":"4947","key":"5574_CR152","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","volume":"2","author":"S Truelove","year":"1955","unstructured":"Truelove S, Witts L (1955) Cortisone in ulcerative colitis. Br Med J 2(4947):1041\u20138","journal-title":"Br Med J"},{"issue":"11","key":"5574_CR153","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/nri2653","volume":"9","author":"J Turner","year":"2009","unstructured":"Turner J (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9(11):799\u2013809","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"5574_CR154","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","volume":"5","author":"D Turner","year":"2007","unstructured":"Turner D, Walsh C, Steinhart A, Griffiths A (2007) Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 5(1):103\u2013110","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"5574_CR155","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/j.gastro.2014.07.023","volume":"147","author":"H Uhlig","year":"2014","unstructured":"Uhlig H, Schwerd T, Koletzko S (2014) The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 147(5):990\u20131007","journal-title":"Gastroenterology"},{"issue":"1","key":"5574_CR156","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1053\/j.gastro.2006.04.020","volume":"131","author":"M Van der Sluis","year":"2006","unstructured":"Van der Sluis M, De Koning B, De Bruijn A (2006) Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131(1):117\u2013129","journal-title":"Gastroenterology"},{"issue":"7","key":"5574_CR157","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","volume":"148","author":"N Vande Casteele","year":"2015","unstructured":"Vande Casteele N, Ferrante M, Van Assche G (2015) Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148(7):1320\u20131329","journal-title":"Gastroenterology"},{"key":"5574_CR158","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/508902","author":"P Vasconcelos","year":"2012","unstructured":"Vasconcelos P, Seito LN, Di Stasi LC, Akiko Hiruma-Lima C, Pellizzon CH (2012) Epicatechin used in the treatment of intestinal inflammatory disease: an analysis by experimental models. Evid Based Complement Alternat Med. https:\/\/doi.org\/10.1155\/2012\/508902","journal-title":"Evid Based Complement Alternat Med"},{"issue":"3","key":"5574_CR159","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/gut.2005.069476","volume":"55","author":"S Vermeire","year":"2006","unstructured":"Vermeire S, Van Assche G, Rutgeerts P (2006) Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55(3):426\u2013431","journal-title":"Gut"},{"issue":"1","key":"5574_CR160","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1053\/j.gastro.2008.04.002","volume":"135","author":"S Vetrano","year":"2008","unstructured":"Vetrano S, Rescigno M, Cera M (2008) Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology 135(1):173\u2013184","journal-title":"Gastroenterology"},{"issue":"1","key":"5574_CR161","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/gut.43.1.29","volume":"43","author":"R Walmsley","year":"1998","unstructured":"Walmsley R, Ayres R, Pounder R, Allan R (1998) A simple clinical colitis activity index. Gut 43(1):29\u201332","journal-title":"Gut"},{"key":"5574_CR162","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.bcp.2018.07.039","volume":"155","author":"K Wang","year":"2018","unstructured":"Wang K, Lv Q, Miao YM, Qiao SM, Dai Y, Wei ZF (2018) Cardamonin, a natural flavone, alleviates inflammatory bowel disease by the inhibition of NLRP3 inflammasome activation via an AhR\/Nrf2\/NQO1 pathway. Biochem Pharmacol 155:494\u2013509","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"5574_CR163","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nm.4307","volume":"23","author":"N West","year":"2017","unstructured":"West N, Hegazy A, Owens B (2017) Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 23(5):579\u2013589","journal-title":"Nat Med"},{"issue":"5","key":"5574_CR164","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.bjp.0707645","volume":"153","author":"B Whittle","year":"2008","unstructured":"Whittle B, Varga C, Berko A (2008) Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. Br J Pharmacol 153(5):983\u2013991","journal-title":"Br J Pharmacol"},{"issue":"7","key":"5574_CR165","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/nprot.2017.044","volume":"12","author":"S Wirtz","year":"2017","unstructured":"Wirtz S, Popp V, Kindermann M (2017) Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc 12(7):1295\u20131309","journal-title":"Nat Protoc"},{"issue":"2","key":"5574_CR166","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/imm.12639","volume":"149","author":"D Withers","year":"2016","unstructured":"Withers D (2016) Innate lymphoid cell regulation of adaptive immunity. Immunology 149(2):123\u2013130","journal-title":"Immunology"},{"key":"5574_CR167","doi-asserted-by":"crossref","unstructured":"Woods ME (2017) Fundamentals of immunology and inflammation. Nanomedicine for inflammatory diseases. CRC Press, pp 3\u201338","DOI":"10.1201\/9781315152356-2"},{"issue":"4","key":"5574_CR168","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"S Ytterberg","year":"2022","unstructured":"Ytterberg S, Bhatt D, Mikuls T (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316\u2013326","journal-title":"N Engl J Med"},{"key":"5574_CR169","doi-asserted-by":"publisher","DOI":"10.1177\/20587392211067292","volume":"19","author":"X Yu","year":"2021","unstructured":"Yu X, Liu Y (2021) Diosmetin attenuate experimental ulcerative colitis in rats via suppression of NF-\u03baB, TNF-\u03b1 and IL-6 signalling pathways correlated with down-regulation of apoptotic events. Eur J Inflamm 19:20587392211067292","journal-title":"Eur J Inflamm"},{"key":"5574_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.etap.2022.103833","volume":"91","author":"MS Zaghloul","year":"2022","unstructured":"Zaghloul MS, Elshal M, Abdelmageed ME (2022) Preventive empagliflozin activity on acute acetic acid-induced ulcerative colitis in rats via modulation of SIRT-1\/PI3K\/AKT pathway and improving colon barrier. Environ Toxicol Pharmacol 91:103833","journal-title":"Environ Toxicol Pharmacol"},{"issue":"1","key":"5574_CR171","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10787-024-01630-9","volume":"33","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Cao P, Qin D, Zhao Y, Chen X, Ma P (2025) Anti-inflammatory, anti-colitis, and antioxidant effects of columbianadin against DSS-induced ulcerative colitis in rats via alteration of HO-1\/Nrf2 and TLR4-NF-\u03baB signaling pathway. Inflammopharmacology 33(1):341\u2013352","journal-title":"Inflammopharmacology"},{"key":"5574_CR172","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1502849","volume":"11","author":"D Zhao","year":"2025","unstructured":"Zhao D, Ge A, Yan C, Liu X, Yang K, Yan Y, Hao M, Chen J, Daga P, Dai CC (2025) T helper cell 17\/regulatory T cell balance regulates ulcerative colitis and the therapeutic role of natural plant components: a review. Front Med 11:1502849","journal-title":"Front Med"},{"key":"5574_CR173","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ebiom.2018.08.035","volume":"35","author":"M Zhou","year":"2018","unstructured":"Zhou M, Xu W, Wang J, Yan J, Shi Y, Zhang C, Ge W, Wu J, Du P, Chen Y (2018) Boosting mTOR-dependent autophagy via upstream TLR4-MyD88-MAPK signalling and downstream NF-\u03baB pathway quenches intestinal inflammation and oxidative stress injury. EBioMedicine 35:345\u2013360","journal-title":"EBioMedicine"},{"key":"5574_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113651","volume":"154","author":"MH Zohny","year":"2022","unstructured":"Zohny MH, Alrouji M, Alhajlah S, AlOmeir O, Ewees MGE, Ghaffar DMA, El Adle KN, Mohammed OA, Abdeldaiem MSI, El-Bahouty WB, Elrabat A, Zakaria S, Abdel-Nasser ZM, Haleem AA, El-Gharbawy DM, Abdelhady R, Kaddah MMY, Shata A, Saber S (2022) Diacetylrhein, an anthraquinone antiarthritic agent, suppresses dextran sodium sulfate-induced inflammation in rats: a possible mechanism for a protective effect against ulcerative colitis. Biomed Pharmacother 154:113651","journal-title":"Biomed Pharmacother"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05574-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05574-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05574-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:02:34Z","timestamp":1791540154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05574-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":174,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5574"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05574-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not\u00a0applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}